InvestorsHub Logo
Followers 1741
Posts 142358
Boards Moderated 4
Alias Born 09/11/2005

Re: None

Tuesday, 12/28/2021 7:43:43 AM

Tuesday, December 28, 2021 7:43:43 AM

Post# of 56
BBIO-Analysts-NEW-PRICE-TARGETS are double current price after 71% decline in BridgeBio's stock price Monday

J.P. Morgan analyst Anupam Rama's NEW PRICE TARGET for BridgeBio to $36 from $77 based on broad model adjustments, including peak sales estimates and odds of success calculations for acoramidis, after the company's disappointing ATTRibute-CM trial data. Rama keeps Overweight rating as he sees "an interesting catalyst pathway" for the company.

Analyst Eun Yang -Jeffries- NEW PRICE TARGET on BridgeBio is $28. Yang maintained Buy rating on the stock, citing “anticipated proof-of-concept clinical data from pipeline products in 2022-2023.”

Analyst Salim Syed - Mizuho - NEW PRICE TARGET $25 and keeps a Buy rating on the shares.

Analyst Mani Foroohar - SVB Leerink - NEW PRICE TARGET $24 with Outperform rating.







Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BBIO News